Inclusion Criteria:
  -  Adult patients (age â‰¥18 years) with Chronic Myeloid Leukemia in any phase who are initiating ponatinib monotherapy, or for whom ponatinib monotherapy was initiated after ponatinib approval in Germany. [The decision to prescribe ponatinib must have been made prior to enrolment in the study. Patients enrolled in the retrospective part of the study may or may not be still on ponatinib treatment at the time informed consent is given. These retrospective patients should have started Treatment after
     02.02.2015.].
  -  Patients who have the ability to understand the requirements of the study, and provide written informed consent to comply with the study data collection procedures.
  -  Patients with a minimum life expectancy of 3 months
Exclusion Criteria:
  -  Patients previously treated with investigational ponatinib (within a clinical trial)
  -  Patients receiving an investigational agent
  -  Patients who are pregnant and/or breastfeeding
  -  Patients who are pregnant and/or breastfeeding